Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 6;23(9):5208. doi: 10.3390/ijms23095208

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Anti-CD59 antigen-binding Fc fragments (Fcabs) from initial selections of Fcab libraries: (a) HPLC-SEC chromatography of derived mAb² molecules in native conditions (MWS: molecular weight standard); (b) ELISA with coated CD59; (c) Competition of biotinylated HuMax-20 (HX)-BER3 mAb² with HX-BER1, HX-BER2 and HX-BER3; (d) Biolayer interferometry measurement of response to immobilized CD59: HX-BER1 to 3 were applied in 2-fold dilution steps starting from 1 µM. RX: rituximab, TRA: trastuzumab.

Anti-CD59 antigen-binding Fc fragments (Fcabs) from initial selections of Fcab libraries: (a) HPLC-SEC chromatography of derived mAb² molecules in native conditions (MWS: molecular weight standard); (b) ELISA with coated CD59; (c) Competition of biotinylated HuMax-20 (HX)-BER3 mAb² with HX-BER1, HX-BER2 and HX-BER3; (d) Biolayer interferometry measurement of response to immobilized CD59: HX-BER1 to 3 were applied in 2-fold dilution steps starting from 1 µM. RX: rituximab, TRA: trastuzumab.